We have a large and varied tumor model bank comprising over 100 human and 40 murine cell lines, offering a wide choice for your preclinical oncology studies. These cell lines are useful for multiple in vivo experiments, enabling detailed studies of tumor biology, drug efficacy and resistance mechanisms. When implanted in immunocompromised (for CDX models) or immunocompetent (for syngeneic models) mice, our cell lines have robust tumor growth, and most types of cancer seen in patients can be found in our stock.
We are constantly working to expand and update our catalog of tumor models to stay ahead of the evolving landscape of cancer research. This includes the development of new models that represent emerging tumor types and treatment-resistant phenotypes, ensuring that our clients have access to the most relevant and up-to-date models for their research. Our catalog of available tumor models is continually growing, and we encourage you to contact us for the most recent list.
A standout feature of Antineo’s offering is our unique portfolio of tumor models that have been developed to resist to gold standards immunotherapies or chemotherapies. These models are designed to mirror the clinical challenge of acquired resistance that often develops in patients undergoing anticancer therapies. We also offer customizable resistance models tailored to your specific compound or to standard-of-care treatments. These models may be produced in vitro as well as in vivo, allowing you to adjust your treatment strategy in response to actual resistance challenges.
To explore our full range of tumor models and learn more about how we can support your preclinical research, please contact us.
